Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Study Results: Lenvatinib in Renal Cell Carcinoma

January 29th 2016

PD-L1 Expression as a Biomarker in RCC

January 29th 2016

Trial Data on Cabozantinib in Renal Cell Carcinoma

January 29th 2016

Clinical Trial Data Review: Nivolumab Use in RCC

January 29th 2016

Predictive Tools in Renal Cell Carcinoma

January 29th 2016

Selecting Second-Line Agents in Renal Cell Carcinoma

January 29th 2016

Managing Disease Progression in RCC

January 29th 2016

Treating Non-Clear Cell Renal Cell Carcinoma

January 29th 2016

Bone and Brain Metastases in Renal Cell Carcinoma

January 29th 2016

Dosing Sunitinib and Pazopanib in Renal Cell Carcinoma

January 29th 2016

Reviewing Results from COMPARZ and PISCES Clinical Trials

January 29th 2016

Treating Intermediate and Favorable-Risk RCC

January 29th 2016

Prognostic and Predictive Factors in Renal Cell Carcinoma

January 29th 2016

FDA Grants Cabozantinib Priority Review for RCC

January 28th 2016

The FDA has granted a priority review designation to cabozantinib as a treatment for patients with advanced renal cell carcinoma following progression on one prior therapy.

Delayed Decision on CINV Therapy, Priority Review in RCC, and CSS Highlights

January 21st 2016

FDA Grants Priority Review to Lenvatinib/Everolimus Combo for RCC

January 18th 2016

The FDA has granted a priority review designation to the combination of lenvatinib and everolimus as a treatment for patients with metastatic renal cell carcinoma following one prior VEGF-targeted therapy.

Lenvatinib/Everolimus Combo Submitted for Approval in Advanced RCC

January 15th 2016

Regulatory filings have been submitted in the United States and Europe for the combination of lenvatinib and everolimus as a treatment for patients with metastatic renal cell carcinoma following a VEGF-targeted therapy.

High T-Cell Diversity Linked to Better Prognosis in mRCC

January 14th 2016

The VEGFR inhibitor pazopanib was efficacious independent of T-cell receptor–gamma entropy in metastatic renal cell carcinoma setting.

Dramatic Changes on Horizon in Renal Cell Carcinoma

January 12th 2016

The optimal frontline treatment strategy for patients with metastatic renal cell carcinoma could look dramatically different in the next few years, as studies assess combination strategies and predictive biomarkers for immunotherapy and targeted therapies.

Cory Abate-Shen on Bladder Cancer Modeling

January 11th 2016

Cory Abate-Shen, PhD, research faculty, Columbia Urology, Columbia University Medical Center, discusses the challenges of bladder cancer modeling.